Skip to main content

Microbiome-Based Deal Benchmarks in Gastroenterology

Median Upfront
$401M
Range: $214M - $580M
Total Deal Value
$2.0B
Range: $1.3B - $2.8B
Royalty Rate
7% - 13.1%
Tiered up to 17.1%
Dev Milestones
$344M
Range: $225M - $465M
Model Your Deal

Market Analysis

Microbiome-Based therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 microbiome-based asset in gastroenterology is $401M, with total deal values reaching $2.0B. Development milestones average $344M, while regulatory milestones contribute $410M.

The gastroenterology microbiome-based landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for microbiome-based gastroenterology deals range from 7% to 13.1% at the base tier, with tiered escalation reaching 11%-17.1% on blockbuster sales. Commercial milestones averaging $886M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a microbiome-based gastroenterology licensing deal?
Based on our analysis, Phase 2 microbiome-based licensing deals in gastroenterology average $401M in upfront payments, with a range of $214M to $580M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for microbiome-based gastroenterology transactions?
The median total deal value for Phase 2 microbiome-based assets in gastroenterology is $2.0B, ranging from $1.3B to $2.8B. This includes development milestones ($344M), regulatory milestones ($410M), and commercial milestones ($886M).
What royalty rates are standard for microbiome-based deals in gastroenterology?
Base royalty rates for microbiome-based gastroenterology transactions range from 7% to 13.1%, with tiered escalations reaching 11%-17.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in microbiome-based gastroenterology deals?
Microbiome-Based gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($344M) make up the largest share, followed by commercial milestones ($886M) and regulatory milestones ($410M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Gastroenterology

View

Monoclonal Antibody in Gastroenterology

View

Microbiome-Based in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included